clinical trial · NCT05963984
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants
Metastatic Breast CancerLocally Advanced Breast CancerBreast CancerSamuraciclibFulvestrant
brief summary
The purpose of this study is to evaluate the safety and efficacy of samuraciclib in combination with fulvestrant versus fulvestrant alone in adult participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast cancer.
started
Nov 16, 2023
primary completion
Mar 20, 2025
completion
Aug 28, 2025
last updated
Dec 26, 2025
official title
An Open-label, Interventional, Multicenter, Randomized, Phase 2 Study of Fulvestrant With or Without Samuraciclib in Participants With Metastatic or Locally Advanced Hormone Receptor (HR) Positive and Human Epidermal Growth Factor Receptor (HER)2-Negative Breast Cancer (BC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol